P0F.F EGETIS THERAPEUTICS AB

Healthcare Biotechnology Frankfurt Exchange
0.9750 EUR
Close of Nov 12, 2026
0.3615 1.00
Market cap
EUR 453M
P/E
-
P/B
14.03x
ROE
-137.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is P0F.F undervalued?

Graham number

The Graham number of EGETIS THERAPEUTICS AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

EGETIS THERAPEUTICS AB fundamental analysis

No fundamental analysis for EGETIS THERAPEUTICS AB yet.

EGETIS THERAPEUTICS AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About EGETIS THERAPEUTICS AB

Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency. The company was form…

Full company profile